Vaccine Development
& Global Implementation
A Static Infographic Poster + An interactive Data Visualization
This project is aimed to engage public interest in vaccine development and the global effort to combat infectious diseases. It consists of an infographic poster and an interactive wall display.
The poster takes Gardasil – an HPV vaccine – as an example, to explain each crucial and necessary stage it takes, for a novel vaccine to be approved for use in the market. To see how long it takes to make a vaccine, the infographic also includes a comprehensive development timeline for each vaccine preventable disease.
To illustrate whether vaccine was efficient in controlling the disease, the interactive module contains a comparison between disease incidence and vaccination coverage. It also lists the global coverage of a vaccine based on whether a country has set up a vaccination schedule for a particular disease.
Infographic Poster
27" x 36" in size

Interactive Mockup Demo
40" x 25" Wall Display





Faculty advisor
Dr. Jodie Jenkinson
Medium/Software
Adobe Illustrator
Final presentation format
Infographic: 27 x 36 inches wall poster
Interactive wall display: 40 x 25 inches
Primary audience
Lay audience
Work Process
Reference
-
Shi, L., Sings, H. L., Bryan, J. T., Wang, B., Wang, Y., Mach, H., Kosinski, M., Washabaugh, M. W., Sitrin, R. Barr, E. (2006). GARDASIL®: Prophylactic Human Papillomavirus Vaccine Development – From Bench Top to Bed‐side. Clinical Pharmacology & Therapeutics, 81(2), 259-264. doi:10.1038/sj.clpt.6100055
-
Cunningham, A. L., Garcon, N., Leo, O., Friedland, L. R., Strugnell, R., Laupèze, B., Doherty, M., & Stern, P. (2016). Vaccine development: From concept to early clinical testing. Vaccine, 34(52), 6655-6664. https://doi.org/10.1016/j.vaccine.2016.10.016.
-
Callaway, E., (2020, April 28). The race for coronavirus vaccines: a graphical guide. Nature News Feature. https://www.nature.com/articles/d41586-020-01221-y
-
Siddiqui, M. A. A., & Perry, C. M. (2006). Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®). Drugs, 66(9), 1263-1271. https://doi.org/10.2165/00003495-200666090-00008
-
Villa, L. L., Costa, R. L., & Petta, C. A. et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6(5), 271-278. https://doi.org/10.1016/S1470-2045(05)70101-7.
-
Buckland, B. C. (2005). The process development challenge for a new vaccine. Nature Medicine, 11, S16-S19. https://doi.org/10.1038/nm1218
-
Block, S. L., Brown, D. R., & Chatterjee, A. et al. (2010). Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine. The Pediatric Infectious Disease Journal, 29(2), 95-101. doi: 10.1097/INF.0b013e3181b77906.
-
Serdobova, I. & Kieny, MP. (2011). Assembling a Global Vaccine Development Pipeline for Infectious Diseases in the Developing World. American Journal of Public Health, 96, 1554-1559. https://doi.org/10.2105/AJPH.2005.074583